Tristel, the leading producer of contamination and infection control products, announced that it has established a branch office in Berlin, Germany. The company is already selling its proprietary chlorine dioxide chemistry based products in Germany, selling its Wipes System into Ear Nose and Throat and Cardiology hospital units. Tristel is also selling its Stella semi-automated endoscope decontamination system into Urology departments.
TSTL shares have appreciated by 6% over the last year.
Tristel Plc is currently graded b by LCF Research.
Looked at this one before - solid business - but perhaps more of a buy under 50p.
http://www.proactiveinvestors.co.uk/columns/hb-markets/3376/hb-markets-daily-smallcap-newsflash-featuring-advanced-computer-softwarecharacter-group-clyde-process-solutions-innovation-group-and-others-3376.html
Tristel (TSTL, 54.0p, £17.90m), the manufacturer and provider of infection and water treatment products, reports trading for the year ended 30 June 2010 is in line with market consensus PBT of £2.1m, EPS of 5.0p and DPS of 1.8p.
The group has opened a new office in Germany to diversify its exposure to the UK market and enter Europe’s largest healthcare market.
There is no mention of the group’s performance post the results, which is disappointing. Previously the Board believed the Tristel products, which are available in all NHS hospitals, will be resilient to financial constraints. We are not entirely confident about the latter.
The market forecasts 2011 PBT of £2.9m, EPS of 6.5p and DPS of 1.9p. The stock trades on 10x 2010 earnings with a yield of 3.6% and 7.7x 2011 earnings. The lack of information regarding the current financial year encourages us to reduce our recommendation to a HOLD. (Amisha Chohan